Serum Hepatitis B Virus RNA Levels Predict HBeAg Seroconversion and Virological Response in Chronic Hepatitis B Patients with High Viral Load Treated with Nucleos(t)ide Analog

References

• European Association for the Study of the Liver. EASL 2017 clinical practice guidelines on the management of hepatitis B virus infection. J Hepatol. 2017;67(2):370–398. doi:10.1016/j.jhep.2017.03.02128427875
   PubMed Web of Science ®Google Scholar
• Terrault NA, Lok ASF, McMahon BJ, et al. Update on prevention, diagnosis, and treatment of chronic hepatitis B: AASLD 2018 hepatitis B guidance. Clin Liver Dis (Hoboken). 2018;12(1):33–34. doi:10.1002/cld.72830988907
   PubMedGoogle Scholar
• Kock J, Theilmann L, Galle P, Schlicht HJ. Hepatitis B virus nucleic acids associated with human peripheral blood mononuclear cells do not originate from replicating virus. Hepatology. 1996;23(3):405–413. doi:10.1002/hep.5102303038617418
   PubMed Web of Science ®Google Scholar
• Liu S, Zhou B, Valdes JD, Sun J, Guo H. Serum hepatitis B virus RNA: a new potential biomarker for chronic hepatitis B virus infection. Hepatology. 2019;69(4):1816–1827. doi:10.1002/hep.3032530362148
   PubMed Web of Science ®Google Scholar
• Wang J, Shen T, Huang X, et al. Serum hepatitis B virus RNA is encapsidated pregenome RNA that may be associated with persistence of viral infection and rebound. J Hepatol. 2016;65(4):700–710. doi:10.1016/j.jhep.2016.05.02927245431
   PubMed Web of Science ®Google Scholar
• Wang J, Yu Y, Li G, et al. Relationship between serum HBV RNA levels and intrahepatic viral as well as histologic activity markers in entecavir-treated patients. J Hepatol. 2017;pii:S0168–8278(17)32261–4.
   Google Scholar
• Giersch K, Allweiss L, Volz T, Dandri M, Lutgehetmann M. Serum HBV pgRNA as a clinical marker for cccDNA activity. J Hepatol. 2017;66(2):460–462. doi:10.1016/j.jhep.2016.09.02827826059
   PubMed Web of Science ®Google Scholar
• Carey I, Gersch J, Wang B, et al. Pre-genomic HBV RNA and HBcrAg predict outcomes in HBeAg negative chronic hepatitis B patients suppressed on nucleos(t)ide analogue therapy. Hepatology. 2019. doi:10.1002/hep.31026
   Web of Science ®Google Scholar
• Huang YW, Takahashi S, Tsuge M, et al. On-treatment low serum HBV RNA level predicts initial virological response in chronic hepatitis B patients receiving nucleoside analogue therapy. Antivir Ther. 2015;20(4):369–375. doi:10.3851/IMP277724739420
   PubMed Web of Science ®Google Scholar
• Ma G, Lou B, Lv F, Zhao D, Zhang Z, Chen Y. HBcrAg and pgRNA and the therapeutic effect in HBeAg-positive patients receiving anti-viral therapy, baseline serum HBV-RNA is a powerful predictor of response. J Viral Hepat. 2020. doi:10.1111/jvh.13299
   Web of Science ®Google Scholar
• Farag MS, van Campenhout MJH, Pfefferkorn M, et al. Hepatitis B virus RNA as early predictor for response to PEGylated interferon alfa in HBeAg negative chronic hepatitis B. Clin Infect Dis. 2020;pii:ciaa013. doi:10.1093/cid/ciaa013
   Web of Science ®Google Scholar
• Bömmel FV, Bartens A, Mysickova A, et al. Serum hepatitis B virus RNA levels as an early predictor of hepatitis B envelope antigen seroconversion during treatment with polymerase inhibitors. Hepatology. 2015;61(1):66–76. doi:10.1002/hep.2738125132147
   PubMed Web of Science ®Google Scholar
• Liaw YF, Gane E, Leung N, et al. 2-year GLOBE trial results: telbivudine is superior to lamivudine in patients with chronic hepatitis B. Gastroenterology. 2009;136(2):486–495. doi:10.1053/j.gastro.2008.10.02619027013
   PubMed Web of Science ®Google Scholar
• Tseng TC, Liu CJ, Hsu CY, et al. High level of hepatitis B core-related antigen associated with increased risk of hepatocellular carcinoma in patients with chronic HBV infection of intermediate viral load. Gastroenterology. 2019;157(6):1518–1529.e1513. doi:10.1053/j.gastro.2019.08.02831470004
   PubMed Web of Science ®Google Scholar
• Cai S, Li Z, Yu T, Xia M, Peng J. Serum hepatitis B core antibody levels predict HBeAg seroconversion in chronic hepatitis B patients with high viral load treated with nucleos(t)ide analogs. Infect Drug Resist. 2018;11:469–477. doi:10.2147/IDR.S16303829662321
   PubMed Web of Science ®Google Scholar
• Wu Y, Gao C, Cai S, et al. Circulating miR-122 is a predictor for virological response in CHB patients with high viral load treated with nucleos(t)ide analogs. Front Genet. 2019;10:243. doi:10.3389/fgene.2019.0024330967899
   PubMed Web of Science ®Google Scholar
• Fan R, Zhou B, Xu M, et al. Association between negative results from tests for HBV DNA and RNA and durability of response after discontinuation of nucles(t)ide analogue therapy. Clin Gastroenterol Hepatol. 2019;18(3):719–727. doi:10.1016/j.cgh.2019.07.04631362119
   PubMed Web of Science ®Google Scholar
• Lin N, Ye A, Lin J, et al. Diagnostic value of detection of pregenomic RNA in sera of hepatitis B virus-infected patients with different clinical outcomes. J Clin Microbiol. 2020;58(2):pii: e01275–19.
   Web of Science ®Google Scholar
• Huang H, Wang J, Li W, et al. Serum HBV DNA plus RNA shows superiority in reflecting the activity of intrahepatic cccDNA in treatment-naive HBV-infected individuals. J Clin Virol. 2018;99–100:71–78. doi:10.1016/j.jcv.2017.12.016
   PubMed Web of Science ®Google Scholar
• Wu Y, Wen J, Xiao W, Zhang B. Pregenomic RNA: how to assist the management of chronic hepatitis B? Rev Med Virol. 2019;29(4):e2051. doi:10.1002/rmv.205131074177
   PubMed Web of Science ®Google Scholar
• van Campenhout MJH, van Bommel F, Pfefferkorn M, et al. Serum hepatitis B virus RNA predicts response to peginterferon treatment in HBeAg-positive chronic hepatitis B. J Viral Hepat. 2020. doi:10.1111/jvh.13272
   Web of Science ®Google Scholar
• van Bommel F, van Bommel A, Krauel A, et al. Serum HBV RNA as a predictor of peginterferon alfa-2a response in patients with HBeAg-positive chronic hepatitis B. J Infect Dis. 2018;218(7):1066–1074. doi:10.1093/infdis/jiy27029741634
   PubMed Web of Science ®Google Scholar
• Luo H, Zhang XX, Cao LH, et al. Serum hepatitis B virus RNA is a predictor of HBeAg seroconversion and virological response with entecavir treatment in chronic hepatitis B patients. World J Gastroenterol. 2019;25(6):719–728. doi:10.3748/wjg.v25.i6.71930783375
   PubMed Web of Science ®Google Scholar
• Wang J, Yu Y, Li G, et al. Natural history of serum HBV-RNA in chronic HBV infection. J Viral Hepat. 2018;25(9):1038–1047. doi:10.1111/jvh.1290829633430
   PubMed Web of Science ®Google Scholar
• Gu Y, Chen L, Lian Y, et al. Serum HBV pregenomic RNA is correlated with Th1/Th2 immunity in treatment-naive chronic hepatitis B patients. J Med Virol. 2020;92(3):317–328. doi:10.1002/jmv.2561231642539
   PubMed Web of Science ®Google Scholar
• van Campenhout MJH, van Bommel F, Pfefferkorn M, et al. Host and viral factors associated with serum hepatitis B virus RNA levels among patients in need for treatment. Hepatology. 2018;68(3):839–847. doi:10.1002/hep.2987229514389
   PubMed Web of Science ®Google Scholar